Genes	Cancer	Metastasis	Hypoxia
ABAT	-	-	[1]
ADM	[2-5]	[6, 7]	[6]
ATF3	[8-10]	[11]	[12]
CDC6	[13]	[14]	-
CXCL1	[15, 16]	[17, 18]	-
HMGCS1	-	-	-
NR4A1	[19]	-	-
HOXA5	[20, 21]	-	-
ID2	[22-24]	[25]	[26]
ISL1	[27]	[27]	-
LMNB1	-	-	-
SERPINE1	[28-30]	[28-30]	[31]
TPSAB1	[32, 33]	-	[34]
ZFP36	[35, 36]	-	-
CCNE2	[37]	[38]	-
AKAP12	[39, 40]	[41]	[42]
STIP1	[43]	-	-
TIPARP	[44]	-	-
WSB1	[45]	[45]	-
TPSB2	[32, 33]	-	[34]
ASPM	[46]	[46]	-
RHOB	[47]	-	-
CALD1	[48]	-	-
CAPG	[49]	[50]	-
CCNB1	[51, 52]	[53]	-
CKS2	[54]	[54]	-
CLU	[55]	-	[56]
COL9A2	-	-	-
CTGF	[57]	-	[58]
DDB2	[59, 60]	-	-
DUSP1	[61]	[62]	-
DUSP8	-	-	-
DUT	-	-	-
ERBB3	[63]	[64]	-
GAPDH	-	-	-
HSPB1	[65, 66]	-	-
IDI1	[67, 68]	-	-
SP110	-	-	-
IGF2	[69]	-	[70]
ILF3	[71]	-	[71]
JUNB	[72]	[73]	-
LAMA3	[74]	[75]	-
LAMP1	-	-	-
TM4SF1	[76, 77]	[76, 77]	-
NFX1	-	-	-
PDK1	[78, 79]	-	[80]
PGK1	[81]	[82]	-
PHF2	-	-	-
MAPK1	-	-	-
MAP2K1	[83, 84]	-	[85]
RIT1	[86]	-	-
SCD	-	-	-
STAT1	[87]	-	-
TSPYL1	-	-	-
TUBB2A	-	-	-
VEGFA	[88]	-	[88]
PIR	[89]	[89]	-
BHLHB2	[90]	[90]	[91]
TP63	[92]	[93]	-
IER3	[94]	-	[95]
TUBB3	[96]	[97]	[98]
TUBB4	-	-	-
TUBB2C	-	-	-
DDX17	[99]	[100]	-
PSIP1	[101]	-	-
CARHSP1	-	-	-
UHRF1	[102]	-	-
ERO1L	-	-	[103-105]
SMOX	[106]	-	-
DDIT4	[107]	-	[107]
ZCCHC2	-	-	-

ZNF532	-	-	-
ASF1B	-	-	-
MLF1IP	[108, 109]	-	-
CYBRD1	[110, 111]	-	-
TUBB2B	-	-	-
ACTC1	-	-	-
ACTG2	-	-	-
ACYP2	-	-	-
ALOX15B	[112]	-	-
APP	-	-	-
BDH1	-	-	-
KLF9	[113]	-	-
C7	-	-	-
COL12A1	[114]	-	-
CTSB	[115]	-	-
DES	-	-	-
E2F6	[116]	-	-
PHC1	-	-	-
EIF2S3	-	-	-
FHL1	[117]	[117]	-
FLNC	-	-	-
FOS	[118]	-	-
GSTA4	-	-	-
GSTM1	[119, 120]	-	-
GSTM2	-	-	-
GSTM4	[121]	-	-
CFH	-	-	-
ID4	[122]	[122]	-
IDS	-	-	-
IGF1	[123, 124]	-	-
IGFBP1	-	-	-
ABLIM1	-	-	-
M6PR	[125]	-	-
MFAP4	-	-	-
MMP7	[126]	[126]	-
MNT	[127]	-	-
MYH11	[128, 129]	-	-
NFKBIA	[130, 131]	[130, 131]	-
CNTN3	-	-	-
PAX3	[132]	-	-
PRSS1	-	-	-
PRSS2	[133]	-	-
PRSS3	[134]	[134]	-
PRSS8	[135]	-	-
PTGDS	-	-	-
SPP1	[136]	[136]	-
TCEA3	-	-	-
PRDX2	[137]	[138]	-
TGM3	[139]	-	-
VSNL1	[140]	-	-
YWHAZ	[141]	-	-
SLC39A7	-	-	-
PDHX	-	-	-
SLC7A5	[142]	-	-
GPR109B	-	-	-
LITAF	-	-	-
GDF15	[143, 144]	[145]	-
HERPUD1	[146]	-	-
MYL9	-	-	-
STAG3	-	-	-
AKAP2	-	-	-
DDX42	-	-	-
PHLDA1	[147]	[147]	-
MTF2	-	-	-
TPX2	[148]	-	-
PRUNE2	-	-	-
MGRN1	-	-	-
TPSD1	-	-	-
MAFF	-	-	-
OSTF1	-	-	-
PRPF19	-	-	-
RNF141	-	-	-

IER3IP1	-	-	-
DTL	[149]	-	-
STAG3L1	-	-	-
PALMD	-	-	-
PRPF38B	-	-	-
NRIP3	-	-	-
PAK6	[150]	[150]	-
BHLHB3	[151]	-	[151]
PGBD5	-	-	-
FAM57A	[152]	-	-
RMI1	[153]	-	-
APOL6	[154]	-	-
KLHDC3	-	-	-
APCDD1	[155]	-	-
RBM24	-	-	-
GPR109A	-	-	-
STAG3L3	-	-	-
STAG3L2	-	-	-
PALM2-AKAP2	-	-	-
ARVCF	-	-	-
BCAT1	[156]	[157]	-
CFB	-	-	-
DHCR24	[158-160]	[158-160]	-
ETS2	[161, 162]	-	-
SFN	[163, 164]	-	-
HIST1H2AE	-	-	-
HSP90AA1	-	-	-
NDUFB6	-	-	-
PTHLH	[165]	[166]	-
RRM2	[167, 168]	-	-
TRAPPC2	-	-	-
SFRS6	-	-	-
TYMS	[169-171]	-	-
RGS20	[172]	[172]	-
SKAP2	[173]	-	-
SEDLP	-	-	-
ETHE1	-	-	-
LSM14A	-	-	-
ARID5B	-	-	-
LOC440258	-	-	-

1. Madl JE, Royer SM: **Glutamate dependence of GABA levels in neurons of hypoxic and hypoglycemic rat hippocampal slices.** *Neuroscience* 2000, **96:**657-664.
2. Nakamura M, Han B, Nunobiki O, Kakudo K: **Adrenomedullin: a tumor progression factor via angiogenic control.** *Curr Cancer Drug Targets* 2006, **6:**635-643.
3. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bicknell R: **Adrenomedullin and tumour angiogenesis.** *Br J Cancer* 2006, **94:**1-7.
4. Oehler MK, Fischer DC, Orlowska-Volk M, Herrle F, Kieback DG, Rees MC, Bicknell R: **Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer.** *Br J Cancer* 2003, **89:**1927-1933.
5. Zudaire E, Martinez A, Cuttitta F: **Adrenomedullin and cancer.** *Regul Pept* 2003, **112:**175-183.
6. Keleg S, Kayed H, Jiang X, Penzel R, Giese T, Buchler MW, Friess H, Kleeff J: **Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion.** *Int J Cancer* 2007, **121:**21-32.
7. Ramachandran V, Arumugam T, Hwang RF, Greenson JK, Simeone DM, Logsdon CD: **Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR.** *Cancer Res* 2007, **67:**2666-2675.
8. Fan F, Jin S, Amundson SA, Tong T, Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, et al: **ATF3 induction following DNA damage is regulated by distinct**

signaling pathways and over-expression of ATF3 protein suppresses cells growth. *Oncogene* 2002, **21:**7488-7496.
9. Yan C, Wang H, Boyd DD: **ATF3 represses 72-kDa type IV collagenase (MMP-2) expression by antagonizing p53-dependent trans-activation of the collagenase promoter.** *J Biol Chem* 2002, **277:**10804-10812.
10. Yin X, Dewille JW, Hai T: **A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.** *Oncogene* 2008, **27:**2118-2127.
11. Ishiguro T, Nagawa H: **ATF3 gene regulates cell form and migration potential of HT29 colon cancer cells.** *Oncol Res* 2001, **12:**343-346.
12. Chen SC, Liu YC, Shyu KG, Wang DL: **Acute hypoxia to endothelial cells induces activating transcription factor 3 (ATF3) expression that is mediated via nitric oxide.** *Atherosclerosis* 2008, **201:**281-288.
13. Borlado LR, Mendez J: **CDC6: from DNA replication to cell cycle checkpoints and oncogenesis.** *Carcinogenesis* 2008, **29:**237-243.
14. Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, et al: **Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior.** *Cancer Res* 2007, **67:**10899-10909.
15. Dhawan P, Richmond A: **Role of CXCL1 in tumorigenesis of melanoma.** *J Leukoc Biol* 2002, **72:**9-18.
16. Wang B, Hendricks DT, Wamunyokoli F, Parker MI: **A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer.** *Cancer Res* 2006, **66:**3071-3077.
17. Li A, Varney ML, Singh RK: **Constitutive expression of growth regulated oncogene (gro) in human colon carcinoma cells with different metastatic potential and its role in regulating their metastatic phenotype.** *Clin Exp Metastasis* 2004, **21:**571-579.
18. Shintani S, Ishikawa T, Nonaka T, Li C, Nakashiro K, Wong DT, Hamakawa H: **Growth-regulated oncogene-1 expression is associated with angiogenesis and lymph node metastasis in human oral cancer.** *Oncology* 2004, **66:**316-322.
19. Mullican SE, Zhang S, Konopleva M, Ruvolo V, Andreeff M, Milbrandt J, Conneely OM: **Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.** *Nat Med* 2007, **13:**730-735.
20. Raman V, Martensen SA, Reisman D, Evron E, Odenwald WF, Jaffee E, Marks J, Sukumar S: **Compromised HOXA5 function can limit p53 expression in human breast tumours.** *Nature* 2000, **405:**974-978.
21. Rhoads K, Arderiu G, Charboneau A, Hansen SL, Hoffman W, Boudreau N: **A role for Hox A5 in regulating angiogenesis and vascular patterning.** *Lymphat Res Biol* 2005, **3:**240-252.
22. Coppe JP, Itahana Y, Moore DH, Bennington JL, Desprez PY: **Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression.** *Clin Cancer Res* 2004, **10:**2044-2051.
23. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, et al: **Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.** *Oncogene* 2008, **27:**7192-7200.
24. Itahana Y, Singh J, Sumida T, Coppe JP, Parrinello S, Bennington JL, Desprez PY: **Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells.** *Cancer Res* 2003, **63:**7098-7105.
25. Tsunedomi R, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Somura H, Yamada M, Oka M: **Decreased ID2 promotes metastatic potentials of hepatocellular**

carcinoma by altering secretion of vascular endothelial growth factor. *Clin Cancer Res* 2008, **14:**1025-1031.
26. Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, Axelson H: **Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells.** *J Biol Chem* 2004, **279:**39223-39231.
27. Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Kloppel G, Komminoth P, Perren A: **Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.** *Am J Surg Pathol* 2008, **32:**420-425.
28. Binder BR, Mihaly J: **The plasminogen activator inhibitor "paradox" in cancer.** *Immunol Lett* 2008, **118:**116-124.
29. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH: **Evolving role of uPA/uPAR system in human cancers.** *Cancer Treat Rev* 2008, **34:**122-136.
30. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, Kjelgaard S, Mathiasen L, Pedersen KE, Skeldal S, et al: **Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.** *Thromb Haemost* 2004, **91:**438-449.
31. Dimova EY, Samoylenko A, Kietzmann T: **Oxidative stress and hypoxia: implications for plasminogen activator inhibitor-1 expression.** *Antioxid Redox Signal* 2004, **6:**777-791.
32. Nico B, Mangieri D, Crivellato E, Vacca A, Ribatti D: **Mast cells contribute to vasculogenic mimicry in multiple myeloma.** *Stem Cells Dev* 2008, **17:**19-22.
33. Ribatti D, Finato N, Crivellato E, Guidolin D, Longo V, Mangieri D, Nico B, Vacca A, Beltrami CA: **Angiogenesis and mast cells in human breast cancer sentinel lymph nodes with and without micrometastases.** *Histopathology* 2007, **51:**837-842.
34. Maxova H, Novotna J, Vajner L, Tomasova H, Vytasek R, Vizek M, Bacakova L, Valouskova V, Eliasova T, Herget J: **In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells.** *Physiol Res* 2008, **57:**903-910.
35. Shimada H, Ichikawa H, Nakamura S, Katsu R, Iwasa M, Kitabayashi I, Ohki M: **Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF.** *Blood* 2000, **96:**655-663.
36. Stoecklin G, Gross B, Ming XF, Moroni C: **A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA.** *Oncogene* 2003, **22:**3554-3561.
37. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL: **Cell cycle machinery: links with genesis and treatment of breast cancer.** *Adv Exp Med Biol* 2008, **630:**189-205.
38. Muller-Tidow C, Metzger R, Kugler K, Diederichs S, Idos G, Thomas M, Dockhorn-Dworniczak B, Schneider PM, Koeffler HP, Berdel WE, Serve H: **Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.** *Cancer Res* 2001, **61:**647-653.
39. Akakura S, Huang C, Nelson PJ, Foster B, Gelman IH: **Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia.** *Cancer Res* 2008, **68:**5096-5103.
40. Liu Y, Gao L, Gelman IH: **SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.** *BMC Cancer* 2006, **6:**105.

41. Gelman IH, Gao L: **SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways.** *Mol Cancer Res* 2006, **4:**151-158.
42. Choi YK, Kim JH, Kim WJ, Lee HY, Park JA, Lee SW, Yoon DK, Kim HH, Chung H, Yu YS, Kim KW: **AKAP12 regulates human blood-retinal barrier formation by downregulation of hypoxia-inducible factor-1alpha.** *J Neurosci* 2007, **27:**4472-4481.
43. Erlich RB, Kahn SA, Lima FR, Muras AG, Martins RA, Linden R, Chiarini LB, Martins VR, Moura Neto V: **STI1 promotes glioma proliferation through MAPK and PI3K pathways.** *Glia* 2007, **55:**1690-1698.
44. Katoh M, Katoh M: **Identification and characterization of human TIPARP gene within the CCNL amplicon at human chromosome 3q25.31.** *Int J Oncol* 2003, **23:**541-547.
45. Archange C, Nowak J, Garcia S, Moutardier V, Calvo EL, Dagorn JC, Iovanna JL: **The WSB1 gene is involved in pancreatic cancer progression.** *PLoS ONE* 2008, **3:**e2475.
46. Lin SY, Pan HW, Liu SH, Jeng YM, Hu FC, Peng SY, Lai PL, Hsu HC: **ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.** *Clin Cancer Res* 2008, **14:**4814-4820.
47. Couderc B, Pradines A, Rafii A, Golzio M, Deviers A, Allal C, Berg D, Penary M, Teissie J, Favre G: **In vivo restoration of RhoB expression leads to ovarian tumor regression.** *Cancer Gene Ther* 2008, **15:**456-464.
48. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, Kruhoffer M, Laurberg S, Borre M, Wang K, et al: **Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis.** *Mol Cell Proteomics* 2008, **7:**1214-1224.
49. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G: **Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas.** *Int J Cancer* 2008, **123:**2130-2137.
50. Renz M, Betz B, Niederacher D, Bender HG, Langowski J: **Invasive breast cancer cells exhibit increased mobility of the actin-binding protein CapG.** *Int J Cancer* 2008, **122:**1476-1482.
51. Bjorck E, Ek S, Landgren O, Jerkeman M, Ehinger M, Bjorkholm M, Borrebaeck CA, Porwit-MacDonald A, Nordenskjold M: **High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma.** *Blood* 2005, **105:**2908-2915.
52. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, et al: **A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors.** *Endocr Relat Cancer* 2007, **14:**887-900.
53. de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L, Grajkowska W, Perek M, Osterheld MC, Ellison D, et al: **Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.** *Clin Cancer Res* 2008, **14:**4154-4160.
54. Kang MA, Kim JT, Kim JH, Kim SY, Kim YH, Yeom YI, Lee Y, Lee HG: **Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer.** *J Cancer Res Clin Oncol* 2008.

55. Toffanin S, Daidone MG, Miodini P, De Cecco L, Gandellini P, Cappelletti V: **Clusterin: a potential target for improving response to antiestrogens.** *Int J Oncol* 2008, **33:**791-798.
56. Shin JK, Han KA, Kang MY, Kim YS, Park JK, Choi WJ, Lee SA, Lee JH, Choi WS, Paik WY: **Expression of clusterin in normal and preeclamptic placentas.** *J Obstet Gynaecol Res* 2008, **34:**473-479.
57. Bennewith KL, Huang X, Ham CM, Graves EE, Erler JT, Kambham N, Feazell J, Yang GP, Koong A, Giaccia AJ: **The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth.** *Cancer Res* 2009, **69:**775-784.
58. Fuchshofer R, Yu AL, Teng HH, Strauss R, Kampik A, Welge-Lussen U: **Hypoxia/reoxygenation induces CTGF and PAI-1 in cultured human retinal pigment epithelium cells.** *Exp Eye Res* 2008.
59. Kattan Z, Marchal S, Brunner E, Ramacci C, Leroux A, Merlin JL, Domenjoud L, Dauca M, Becuwe P: **Damaged DNA binding protein 2 plays a role in breast cancer cell growth.** *PLoS ONE* 2008, **3:**e2002.
60. Xu QY, Gao Y, Liu Y, Yang WZ, Xu XY: **Identification of differential gene expression profiles of radioresistant lung cancer cell line established by fractionated ionizing radiation in vitro.** *Chin Med J (Engl)* 2008, **121:**1830-1837.
61. Wang Z, Zhou JY, Kanakapalli D, Buck S, Wu GS, Ravindranath Y: **High level of mitogen-activated protein kinase phosphatase-1 expression is associated with cisplatin resistance in osteosarcoma.** *Pediatr Blood Cancer* 2008, **51:**754-759.
62. Komiya Y, Kurabe N, Katagiri K, Ogawa M, Sugiyama A, Kawasaki Y, Tashiro F: **A novel binding factor of 14-3-3beta functions as a transcriptional repressor and promotes anchorage-independent growth, tumorigenicity, and metastasis.** *J Biol Chem* 2008, **283:**18753-18764.
63. Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF: **ErbB3 is required for ductal morphogenesis in the mouse mammary gland.** *Breast Cancer Res* 2008, **10:**R96.
64. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, et al: **A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.** *Oncogene* 2008, **27:**5195-5203.
65. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, Yoo BC: **Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability.** *BMC Cancer* 2008, **8:**286.
66. Oba M, Yano S, Shuto T, Suico MA, Eguma A, Kai H: **IFN-gamma down-regulates Hsp27 and enhances hyperthermia-induced tumor cell death in vitro and tumor suppression in vivo.** *Int J Oncol* 2008, **32:**1317-1324.
67. Bani MR, Nicoletti MI, Alkharouf NW, Ghilardi C, Petersen D, Erba E, Sausville EA, Liu ET, Giavazzi R: **Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.** *Mol Cancer Ther* 2004, **3:**111-121.
68. Tabuchi Y, Ando H, Takasaki I, Feril LB, Jr., Zhao QL, Ogawa R, Kudo N, Tachibana K, Kondo T: **Identification of genes responsive to low intensity pulsed ultrasound in a human leukemia cell line Molt-4.** *Cancer Lett* 2007, **246:**149-156.
69. Suzuki H, Li Y, Dong X, Hassan MM, Abbruzzese JL, Li D: **Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer.** *Cancer Epidemiol Biomarkers Prev* 2008, **17:**3467-3473.
70. Nakao K, Aoyama M, Fukuoka H, Fujita M, Miyazawa K, Asai K, Goto S: **IGF2 modulates the microenvironment for osteoclastogenesis.** *Biochem Biophys Res Commun* 2009, **378:**462-466.

71. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP: **Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis.** *Mol Cell Biol* 2008, **28:**772-783.
72. Piechaczyk M, Farras R: **Regulation and function of JunB in cell proliferation.** *Biochem Soc Trans* 2008, **36:**864-867.
73. Konishi N, Shimada K, Nakamura M, Ishida E, Ota I, Tanaka N, Fujimoto K: **Function of JunB in transient amplifying cell senescence and progression of human prostate cancer.** *Clin Cancer Res* 2008, **14:**4408-4416.
74. Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, Albertson DG: **Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma.** *Oncogene* 2005, **24:**4232-4242.
75. Hirai Y, Utsugi K, Takeshima N, Kawamata Y, Furuta R, Kitagawa T, Kawaguchi T, Hasumi K, Noda T: **Putative gene loci associated with carcinogenesis and metastasis of endocervical adenocarcinomas of uterus determined by conventional and array-based CGH.** *Am J Obstet Gynecol* 2004, **191:**1173-1182.
76. Kao YR, Shih JY, Wen WC, Ko YP, Chen BM, Chan YL, Chu YW, Yang PC, Wu CW, Roffler SR: **Tumor-associated antigen L6 and the invasion of human lung cancer cells.** *Clin Cancer Res* 2003, **9:**2807-2816.
77. Lekishvili T, Fromm E, Mujoomdar M, Berditchevski F: **The tumour-associated antigen L6 (L6-Ag) is recruited to the tetraspanin-enriched microdomains: implication for tumour cell motility.** *J Cell Sci* 2008, **121:**685-694.
78. Iorns E, Lord CJ, Ashworth A: **Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization.** *Biochem J* 2009, **417:**361-370.
79. Peifer C, Alessi DR: **New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen.** *Biochem J* 2009, **417:**e5-7.
80. Vigano A, Ripamonti M, De Palma S, Capitanio D, Vasso M, Wait R, Lundby C, Cerretelli P, Gelfi C: **Proteins modulation in human skeletal muscle in the early phase of adaptation to hypobaric hypoxia.** *Proteomics* 2008, **8:**4668-4679.
81. Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, Hsu CI, Lin WC, Lai MK, Lin JY: **MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells.** *Cancer Lett* 2009, **273:**35-43.
82. Zieker D, Konigsrainer I, Traub F, Nieselt K, Knapp B, Schillinger C, Stirnkorb C, Fend F, Northoff H, Kupka S, et al: **PGK1 a potential marker for peritoneal dissemination in gastric cancer.** *Cell Physiol Biochem* 2008, **21:**429-436.
83. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, et al: **Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.** *Cancer Res* 2008, **68:**5524-5528.
84. Shama J, Garcia-Medina R, Pouyssegur J, Vial E: **Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells.** *Biochem Biophys Res Commun* 2008, **372:**845-849.
85. Bajpai AK, Blaskova E, Pakala SB, Zhao T, Glasgow WC, Penn JS, Johnson DA, Rao GN: **15(S)-HETE production in human retinal microvascular endothelial cells by hypoxia: Novel role for MEK1 in 15(S)-HETE induced angiogenesis.** *Invest Ophthalmol Vis Sci* 2007, **48:**4930-4938.

86. Hoshino M, Yoshimori T, Nakamura S: **Small GTPase proteins Rin and Rit Bind to PAR6 GTP-dependently and regulate cell transformation.** *J Biol Chem* 2005, **280:**22868-22874.
87. Klampfer L: **The role of signal transducers and activators of transcription in colon cancer.** *Front Biosci* 2008, **13:**2888-2899.
88. Goudar RK, Vlahovic G: **Hypoxia, angiogenesis, and lung cancer.** *Curr Oncol Rep* 2008, **10:**277-282.
89. Sun JY, Guo W, An J, Yuan Q, Zhao FK: **[Analysis of differentially expressed lung metastasis-associated proteins in adenoid cystic carcinoma cell lines].** *Zhonghua Kou Qiang Yi Xue Za Zhi* 2004, **39:**114-117.
90. Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M, Saitoh M, Miyazawa K, Imamura T, Miyazono K: **Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1.** *Cancer Res* 2007, **67:**9694-9703.
91. Choi SM, Cho HJ, Cho H, Kim KH, Kim JB, Park H: **Stra13/DEC1 and DEC2 inhibit sterol regulatory element binding protein-1c in a hypoxia-inducible factor-dependent mechanism.** *Nucleic Acids Res* 2008, **36:**6372-6385.
92. Khokhar SK, Kommagani R, Kadakia MP: **Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes.** *Cell Res* 2008, **18:**1061-1073.
93. Gu X, Coates PJ, Boldrup L, Nylander K: **p63 contributes to cell invasion and migration in squamous cell carcinoma of the head and neck.** *Cancer Lett* 2008, **263:**26-34.
94. Hu Y, Sun H, Drake J, Kittrell F, Abba MC, Deng L, Gaddis S, Sahin A, Baggerly K, Medina D, Aldaz CM: **From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies.** *Cancer Res* 2004, **64:**7748-7755.
95. Tang Y, Pacary E, Freret T, Divoux D, Petit E, Schumann-Bard P, Bernaudin M: **Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke.** *Neurobiol Dis* 2006, **21:**18-28.
96. Cicchillitti L, Penci R, Di Michele M, Filippetti F, Rotilio D, Donati MB, Scambia G, Ferlini C: **Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin.** *Mol Cancer Ther* 2008, **7:**2070-2079.
97. Izutsu N, Maesawa C, Shibazaki M, Oikawa H, Shoji T, Sugiyama T, Masuda T: **Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.** *Int J Oncol* 2008, **32:**1227-1235.
98. Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C: **Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.** *Gene* 2008, **409:**100-108.
99. Somura H, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Tsunedomi R, Yamada-Okabe H, Sawamura M, Eramoto M, Miyamoto T, et al: **A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy.** *Oncol Rep* 2008, **19:**489-495.
100. Tan X, Zhai Y, Chang W, Hou J, He S, Lin L, Yu Y, Xu D, Xiao J, Ma L, et al: **Global analysis of metastasis-associated gene expression in primary cultures from clinical specimens of clear-cell renal-cell carcinoma.** *Int J Cancer* 2008, **123:**1080-1088.
101. Yokoyama A, Cleary ML: **Menin critically links MLL proteins with LEDGF on cancer-associated target genes.** *Cancer Cell* 2008, **14:**36-46.

102. Achour M, Jacq X, Ronde P, Alhosin M, Charlot C, Chataigneau T, Jeanblanc M, Macaluso M, Giordano A, Hughes AD, et al: **The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression.** *Oncogene* 2008, **27:**2187-2197.
103. Baker KM, Chakravarthi S, Langton KP, Sheppard AM, Lu H, Bulleid NJ: **Low reduction potential of Ero1alpha regulatory disulphides ensures tight control of substrate oxidation.** *Embo J* 2008, **27:**2988-2997.
104. May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E: **Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer.** *Oncogene* 2005, **24:**1011-1020.
105. Yorita Y: **[Augmented expression of endoplasmic reticulum oxidoreductin 1-like (ERO1-L) under a hypoxic condition].** *Hokkaido Igaku Zasshi* 2005, **80:**87-93.
106. Hogarty MD, Norris MD, Davis K, Liu X, Evageliou NF, Hayes CS, Pawel B, Guo R, Zhao H, Sekyere E, et al: **ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma.** *Cancer Res* 2008, **68:**9735-9745.
107. Schneider A, Younis RH, Gutkind JS: **Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.** *Neoplasia* 2008, **10:**1295-1302.
108. Hanissian SH, Teng B, Akbar U, Janjetovic Z, Zhou Q, Duntsch C, Robertson JH: **Regulation of myeloid leukemia factor-1 interacting protein (MLF1IP) expression in glioblastoma.** *Brain Res* 2005, **1047:**56-64.
109. Suzuki H, Arakawa Y, Ito M, Saito S, Takeda N, Yamada H, Horiguchi-Yamada J: **MLF1-interacting protein is mainly localized in nucleolus through N-terminal bipartite nuclear localization signal.** *Anticancer Res* 2007, **27:**1423-1430.
110. Boult J, Roberts K, Brookes MJ, Hughes S, Bury JP, Cross SS, Anderson GJ, Spychal R, Iqbal T, Tselepis C: **Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma.** *Clin Cancer Res* 2008, **14:**379-387.
111. Brookes MJ, Hughes S, Turner FE, Reynolds G, Sharma N, Ismail T, Berx G, McKie AT, Hotchin N, Anderson GJ, et al: **Modulation of iron transport proteins in human colorectal carcinogenesis.** *Gut* 2006, **55:**1449-1460.
112. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, et al: **Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.** *Neoplasia* 2005, **7:**280-293.
113. Kang L, Lu B, Xu J, Hu H, Lai M: **Downregulation of Kruppel-like factor 9 in human colorectal cancer.** *Pathol Int* 2008, **58:**334-338.
114. Storlazzi CT, Wozniak A, Panagopoulos I, Sciot R, Mandahl N, Mertens F, Debiec-Rychter M: **Rearrangement of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22).** *Int J Cancer* 2006, **118:**1972-1976.
115. Rose PP, Bogyo M, Moses AV, Fruh K: **Insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus.** *J Virol* 2007, **81:**8050-8062.
116. Yang WW, Wang ZH, Zhu Y, Yang HT: **E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1.** *Cell Death Differ* 2007, **14:**807-817.

117. Sakashita K, Mimori K, Tanaka F, Kamohara Y, Inoue H, Sawada T, Hirakawa K, Mori M: **Clinical significance of loss of Fhl1 expression in human gastric cancer.** *Ann Surg Oncol* 2008, **15:**2293-2300.
118. Durchdewald M, Guinea-Viniegra J, Haag D, Riehl A, Lichter P, Hahn M, Wagner EF, Angel P, Hess J: **Podoplanin is a novel fos target gene in skin carcinogenesis.** *Cancer Res* 2008, **68:**6877-6883.
119. Tiwawech D, Chindavijak S, Karalak A, Ishida T: **Real-time PCR assay for rapid detection of GSTM1 polymorphism in nasopharyngeal carcinoma patients.** *Asian Pac J Cancer Prev* 2008, **9:**233-237.
120. Traka M, Gasper AV, Melchini A, Bacon JR, Needs PW, Frost V, Chantry A, Jones AM, Ortori CA, Barrett DA, et al: **Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate.** *PLoS ONE* 2008, **3:**e2568.
121. Liloglou T, Walters M, Maloney P, Youngson J, Field JK: **A T2517C polymorphism in the GSTM4 gene is associated with risk of developing lung cancer.** *Lung Cancer* 2002, **37:**143-146.
122. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, Knuchel R, Dahl E: **Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer.** *BMC Cancer* 2008, **8:**154.
123. Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D, Kindler V, Stamenkovic I: **IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.** *PLoS ONE* 2008, **3:**e2634.
124. Reeves SG, Rich D, Meldrum CJ, Colyvas K, Kurzawski G, Suchy J, Lubinski J, Scott RJ: **IGF1 is a modifier of disease risk in hereditary non-polyposis colorectal cancer.** *Int J Cancer* 2008, **123:**1339-1343.
125. O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD: **Insulin-like growth factor-II/mannose 6-phosphate receptor overexpression reduces growth of choriocarcinoma cells in vitro and in vivo.** *Endocrinology* 2002, **143:**4287-4294.
126. Zhang JQ, Wan YL, Liu YC, Wang X, Tang JQ, Wu T, Zhu J, Pan YS: **The FVIIa-tissue factor complex induces the expression of MMP7 in LOVO cells in vitro.** *Int J Colorectal Dis* 2008, **23:**971-978.
127. Hooker CW, Hurlin PJ: **Of Myc and Mnt.** *J Cell Sci* 2006, **119:**208-216.
128. Alhopuro P, Karhu A, Winqvist R, Waltering K, Visakorpi T, Aaltonen LA: **Somatic mutation analysis of MYH11 in breast and prostate cancer.** *BMC Cancer* 2008, **8:**263.
129. Sammalkorpi H, Alhopuro P, Niittymaki I, Orntoft TF, Hokland P, Karhu A, Aaltonen LA: **Mutation analysis of MYH11 in acute myeloid leukemia.** *Leuk Lymphoma* 2008, **49:**1829-1831.
130. Bu H, Rosdahl I, Sun XF, Zhang H: **Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients.** *J Cancer Res Clin Oncol* 2007, **133:**859-866.
131. Gao J, Pfeifer D, He LJ, Qiao F, Zhang Z, Arbman G, Wang ZL, Jia CR, Carstensen J, Sun XF: **Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations.** *Scand J Gastroenterol* 2007, **42:**345-350.
132. Lesiak K, Sztiller-Sikorska M, Czyz M: **[Transcription factors in the development and progression of melanoma].** *Postepy Hig Med Dosw (Online)* 2007, **61:**576-595.
133. Vilen ST, Nyberg P, Hukkanen M, Sutinen M, Ylipalosaari M, Bjartell A, Paju A, Haaparanta V, Stenman UH, Sorsa T, Salo T: **Intracellular co-localization of**

trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. *Exp Cell Res* 2008, **314:**914-926.
134. Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani M: **Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium.** *BMC Genomics* 2008, **9:**201.
135. Verghese GM, Gutknecht MF, Caughey GH: **Prostasin regulates epithelial monolayer function: cell-specific Gpld1-mediated secretion and functional role for GPI anchor.** *Am J Physiol Cell Physiol* 2006, **291:**C1258-1270.
136. Oler G, Camacho CP, Hojaij FC, Michaluart P, Jr., Riggins GJ, Cerutti JM: **Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.** *Clin Cancer Res* 2008, **14:**4735-4742.
137. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T: **Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas.** *Cancer Res* 2006, **66:**6080-6086.
138. Carta F, Demuro PP, Zanini C, Santona A, Castiglia D, D'Atri S, Ascierto PA, Napolitano M, Cossu A, Tadolini B, et al: **Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases.** *Melanoma Res* 2005, **15:**235-244.
139. Liu W, Yu ZC, Cao WF, Ding F, Liu ZH: **Functional studies of a novel oncogene TGM3 in human esophageal squamous cell carcinoma.** *World J Gastroenterol* 2006, **12:**3929-3932.
140. Fu J, Fong K, Bellacosa A, Ross E, Apostolou S, Bassi DE, Jin F, Zhang J, Cairns P, Ibanez de Caceres I, et al: **VILIP-1 downregulation in non-small cell lung carcinomas: mechanisms and prediction of survival.** *PLoS ONE* 2008, **3:**e1698.
141. Ralhan R, Desouza LV, Matta A, Chandra Tripathi S, Ghanny S, Datta Gupta S, Bahadur S, Siu KW: **Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry.** *Mol Cell Proteomics* 2008, **7:**1162-1173.
142. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, Kim do K: **BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells.** *Biol Pharm Bull* 2008, **31:**1096-1100.
143. Scrideli CA, Carlotti CG, Jr., Okamoto OK, Andrade VS, Cortez MA, Motta FJ, Lucio-Eterovic AK, Neder L, Rosemberg S, Oba-Shinjo SM, et al: **Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR.** *J Neurooncol* 2008, **88:**281-291.
144. Wan F, Miao X, Quraishi I, Kennedy V, Creek KE, Pirisi L: **Gene expression changes during HPV-mediated carcinogenesis: a comparison between an in vitro cell model and cervical cancer.** *Int J Cancer* 2008, **123:**32-40.
145. Zimmers TA, Jin X, Gutierrez JC, Acosta C, McKillop IH, Pierce RH, Koniaris LG: **Effect of in vivo loss of GDF-15 on hepatocellular carcinogenesis.** *J Cancer Res Clin Oncol* 2008, **134:**753-759.
146. Joo JH, Liao G, Collins JB, Grissom SF, Jetten AM: **Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response.** *Cancer Res* 2007, **67:**7929-7936.

147. Neef R, Kuske MA, Prols E, Johnson JP: **Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation.** *Cancer Res* 2002, **62:**5920-5929.
148. Xia F, Canovas PM, Guadagno TM, Altieri DC: **A survivin-ran complex regulates spindle formation in tumor cells.** *Mol Cell Biol* 2008, **28:**5299-5311.
149. Ueki T, Nishidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T: **Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells.** *Oncogene* 2008, **27:**5672-5683.
150. Kaur R, Yuan X, Lu ML, Balk SP: **Increased PAK6 expression in prostate cancer and identification of PAK6 associated proteins.** *Prostate* 2008, **68:**1510-1516.
151. Nakamura H, Tanimoto K, Hiyama K, Yunokawa M, Kawamoto T, Kato Y, Yoshiga K, Poellinger L, Hiyama E, Nishiyama M: **Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2.** *Oncogene* 2008, **27:**4200-4209.
152. Pan DN, Li JJ, Wei L, Yao M, Wan DF, Gu JR: **Inhibitory effect of CT120B, an alternative splice variant of CT120A, on lung cancer cell growth.** *Acta Biochim Biophys Sin (Shanghai)* 2005, **37:**588-592.
153. Broberg K, Hoglund M, Gustafsson C, Bjork J, Ingvar C, Albin M, Olsson H: **Genetic variant of the human homologous recombination-associated gene RMI1 (S455N) impacts the risk of AML/MDS and malignant melanoma.** *Cancer Lett* 2007, **258:**38-44.
154. Liu Z, Lu H, Jiang Z, Pastuszyn A, Hu CA: **Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells.** *Mol Cancer Res* 2005, **3:**21-31.
155. Takahashi M, Fujita M, Furukawa Y, Hamamoto R, Shimokawa T, Miwa N, Ogawa M, Nakamura Y: **Isolation of a novel human gene, APCDD1, as a direct target of the beta-Catenin/T-cell factor 4 complex with probable involvement in colorectal carcinogenesis.** *Cancer Res* 2002, **62:**5651-5656.
156. Zhou W, Feng X, Li H, Wang L, Li H, Zhu B, Zhang H, Yao K, Ren C: **Functional evidence for a nasopharyngeal carcinoma-related gene BCAT1 located at 12p12.** *Oncol Res* 2007, **16:**405-413.
157. Yoshikawa R, Yanagi H, Shen CS, Fujiwara Y, Noda M, Yagyu T, Gega M, Oshima T, Yamamura T, Okamura H, et al: **ECA39 is a novel distant metastasis-related biomarker in colorectal cancer.** *World J Gastroenterol* 2006, **12:**5884-5889.
158. Bonaccorsi L, Luciani P, Nesi G, Mannucci E, Deledda C, Dichiara F, Paglierani M, Rosati F, Masieri L, Serni S, et al: **Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer.** *Lab Invest* 2008, **88:**1049-1056.
159. Di Stasi D, Vallacchi V, Campi V, Ranzani T, Daniotti M, Chiodini E, Fiorentini S, Greeve I, Prinetti A, Rivoltini L, et al: **DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis.** *Int J Cancer* 2005, **115:**224-230.
160. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G: **Evolution of the androgen receptor pathway during progression of prostate cancer.** *Cancer Res* 2006, **66:**5012-5020.
161. De la Houssaye G, Vieira V, Masson C, Beermann F, Dufier JL, Menasche M, Abitbol M: **ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.** *Mol Vis* 2008, **14:**1912-1928.

162. Xu D, Dwyer J, Li H, Duan W, Liu JP: **Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc.** *J Biol Chem* 2008, **283:**23567-23580.
163. Kovacheva VP, Davison JM, Mellott TJ, Rogers AE, Yang S, O'Brien MJ, Blusztajn JK: **Raising gestational choline intake alters gene expression in DMBA-evoked mammary tumors and prolongs survival.** *Faseb J* 2009, **23:**1054-1063.
164. Wang Z, Trope CG, Suo Z, Troen G, Yang G, Nesland JM, Holm R: **The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas.** *BMC Cancer* 2008, **8:**308.
165. Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL, Mao L, Wong DT, Zhou X: **Transcriptomic dissection of tongue squamous cell carcinoma.** *BMC Genomics* 2008, **9:**69.
166. Nguyen ST, Hasegawa S, Tsuda H, Tomioka H, Ushijima M, Noda M, Omura K, Miki Y: **Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma.** *Cancer Sci* 2007, **98:**740-746.
167. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, et al: **Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.** *PLoS ONE* 2008, **3:**e3695.
168. Duxbury MS, Whang EE: **RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness.** *Biochem Biophys Res Commun* 2007, **354:**190-196.
169. Aarhus M, Bruland O, Bredholt G, Lybaek H, Husebye ES, Krossnes BK, Vedeler C, Wester K, Lund-Johansen M, Knappskog PM: **Microarray analysis reveals down-regulation of the tumour suppressor gene WWOX and up-regulation of the oncogene TYMS in intracranial sporadic meningiomas.** *J Neurooncol* 2008, **88:**251-259.
170. Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, Shin MH, Park KS, Shin MG, Choi JS, Kim HJ: **Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma.** *Br J Haematol* 2008, **140:**287-294.
171. Zhai X, Gao J, Hu Z, Tang J, Qin J, Wang S, Wang X, Jin G, Liu J, Chen W, et al: **Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.** *BMC Cancer* 2006, **6:**138.
172. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, et al: **The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.** *BMC Med Genomics* 2008, **1:**13.
173. Harada T, Chelala C, Bhakta V, Chaplin T, Caulee K, Baril P, Young BD, Lemoine NR: **Genome-wide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays.** *Oncogene* 2008, **27:**1951-1960.